PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
Processa Pharmaceuticals announced the acquisition of Vidya Therapeutics, gaining VT-7208, a next-generation BTK inhibitor. Concurrently, Processa raised approximately $200 million in a private placement from leading healthcare investors, securing funding through key clinical milestones expected until mid-2029. VT-7208 targets multiple diseases inc…